GW Pharma (GWPH) Tops Q3 EPS by 81c as Revenues Beat

GW Pharma (NASDAQ: GWPH) reported Q3 EPS of ($0.04), $0.81 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $91 million versus the consensus estimate of $85.32 million.

“In this first year of launch, we are pleased to report continued Epidiolex revenue growth in the US. Receptivity to the introduction of this breakthrough treatment continues to be highly encouraging as a result of positive physician and patient experiences as well as strong payer coverage,” stated Justin Gover, GW’s Chief Executive Officer. “We see significant opportunity for the short, medium and long term and believe that all the fundamentals are in place to make Epidiolex a very successful brand. We can expect to see additional momentum from Europe as well as the launch of the Tuberous Sclerosis indication during 2020. On top of this, GW is ideally placed to consolidate its leadership in cannabinoid science through advancing several mid and late stage pipeline programs in the months ahead.”

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Aon names interim CFO as Edmund Reese exits the firm
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown